Advertisements

Мебикар

Quick links to important sections

Мебикар

Selected form

Advertisements
Advertisements

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Мебикар

Quick Facts Overview

Property Description
Active ingredient Temgicoluril (Tetramethyltetraazabicyclooctandione)
Form Tablet or Hard Capsule (Oral Administration)
Pharmacological class Anxiolytic and Nootropic Agent
Common use Reduction of emotional tension and anxiety
Origin Synthetic, bicyclic bis-ureas derivative

What Type of Medication is Мебикар (Temgicoluril)?

Мебикар is a synthetic compound categorized as a central nervous system agent that operates as both an anxiolytic and a nootropic agent. Its official non-proprietary chemical designation is Temgicoluril. Within the ATC Classification system, it is grouped among "Other psychostimulants and nootropics." This classification indicates that the medication provides a functional balance between relieving anxiety and supporting mental performance.

Temgicoluril is characterized by a mechanism that alleviates feelings of fear and irritability without typically inducing the pronounced sedation or muscle relaxation characteristic of traditional benzodiazepines.

Composition, Origin, and Available Forms

The medication's active constituent is the small molecule, Tetramethyltetraazabicyclooctandione (Temgicoluril), which is of synthetic origin and derived from the bicyclic bis-ureas structure.

Мебикар is manufactured as a single-ingredient product designed for oral administration, primarily supplied as a tablet or a hard capsule. Its profile is positioned for patients who require relief from emotional tension or anxiety while needing to maintain cognitive clarity and productivity, differentiating it from purely sedating alternatives.

General Therapeutic Purpose and Profile

The fundamental purpose of Мебикар is to act as a psychological stabilizer, mitigating emotional states such as feelings of inner tension, unrest, fear, and irritability by selectively modulating activity within the brain's emotional zones. This therapeutic effect is achieved without causing significant motor impairment or pronounced drowsiness. Consequently, its design prioritizes the reduction of emotional distress while preserving the user's normal capacity for focused mental and physical activity.

Advertisements

What side effects are possible with Мебикар?

Possible Side Effects and Safety Information

Мебикар (Mebicar) is generally considered to have a favorable safety profile and is associated with low toxicity. Most reported adverse reactions are rare, mild, and transient. Side effects may occur, particularly at the beginning of therapy or with higher doses.

Adverse Reactions and Systemic Effects

Adverse effects are documented primarily in the following system-organ classes:

  • Systemic/Cardiovascular: A temporary, usually non-clinically significant decrease in blood pressure (hypotension) and a mild decrease in body temperature (hypothermia) of 1.0–1.5, C have been observed. These effects are generally transient and typically resolve after the completion of treatment.
  • Gastrointestinal: Dyspeptic symptoms, such as indigestion or mild gastrointestinal discomfort, have been reported rarely.
  • Dermatologic/Hypersensitivity: Rare allergic reactions, including skin rash or itching, may occur. The development of any hypersensitivity symptoms necessitates the discontinuation of the drug.

Contraindications and Safety Restrictions

Мебикар is contraindicated in individuals with known hypersensitivity to the active substance or any of the excipients. Safety information restricts its use in certain populations:

Population Safety Consideration
Pregnancy/Lactation Contraindicated due to insufficient data on safety in these populations.
Pediatric Use Not recommended for children under 18 years of age, as efficacy and safety have not been adequately established.

In cases where the transient decrease in blood pressure or body temperature occurs, treatment cessation is typically not required unless the symptoms become pronounced or severe. Patients should be monitored for the development of allergic reactions, as these require immediate discontinuation of therapy.

Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Domain Official Regulatory Statements
Documented Manifestations Symptoms are rare. Manifestations include mild gastrointestinal upset, transient hypotension, and mild hypothermia (a temperature drop of 1-1.5 C).
Toxicity Profile The substance is classified as having a low toxicity profile, with no severe adverse events documented in regulatory summaries, even following ingestions far exceeding therapeutic levels.
Emergency Response No specific antidote is known. Management is restricted to symptomatic and supportive treatment and general detoxification measures.
When to Seek Help Urgent medical attention must be sought for the application of general detoxification measures (such as gastric lavage) and clinical monitoring.
Population Notes Monitoring for drug accumulation is required in patients with renal impairment due to the primary route of excretion.

Official Overdose Protocol

Official overdose statements:

  • The overdose profile is characterized by low toxicity, with manifestations limited to rare, mild, and non-life-threatening signs.
  • No specific antidote exists, mandating supportive treatment and general detoxification procedures.
  • Clinical monitoring, particularly of blood pressure, is required following high exposure.

Connection to the overall overdose profile: Regulatory documents define the overdose profile by its low toxicity, indicating severe outcomes are not anticipated. However, the official guidance mandates that medical attention be sought immediately for the application of standardized general detoxification measures and clinical monitoring (including blood pressure monitoring) due to the absence of a specific antidote.

Advertisements

Therapeutic Uses of Мебикар

The therapeutic application of Мебикар (Temgicoluril) is centered on providing relief for emotional distress and associated functional symptoms, while generally supporting the maintenance of mental clarity and productivity. It is applied in clinical settings marked by heightened emotional tension and vegetative imbalance.

Categorized among psycho-stimulants and nootropics, the medication has a role in managing psychological and cognitive symptoms. It is generally applied in contexts marked by increased discomfort or tension and may assist with managing symptoms that interfere with daily comfort.

It is used to help address symptoms across several categories, including inner emotional tension, restlessness, irritability, fear, functional cardialgias linked to autonomic imbalance, and emotional strain during nicotine cessation. The primary therapeutic profile may assist with easing the overall emotional burden, supporting patients in coping more steadily with these emotionally disruptive manifestations.

“The primary benefit sought by patients is achieving emotional balance and clarity without the pronounced sedative effects often associated with traditional anxiolytics.”

Quick Fact: Relief for Emotional Tension and Functional Stability

The medication is relevant when symptomatic support is needed, as it generally allows the patient to maintain focused mental activity. This profile is beneficial in clinical scenarios where the patient must preserve functional stability, such as during work or study. Furthermore, it is applied to help address associated emotional manifestations when used in combination with certain other psychotropic medications.

Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Мебикар — Official Regulatory Information

Мебикар (Temgicoluril) is governed by strict population eligibility rules outlined in official regulatory documents. Use of the medicine is generally permitted for adults (age 18 years and older), provided no absolute prohibitions exist.


Eligibility Scope

Classification Official Regulatory Status
Populations for whom use is allowed Adults (age 18 years and older).
Populations for whom use is not recommended Children and adolescents under 18 years of age.
Populations for whom use is contraindicated Hypersensitivity, Pregnancy, and Lactation.

Eligibility Classifications (High-Level)

Classification Constraint
Age-related eligibility rules Not recommended for those under 18 as safety and efficacy data are not established for this group.
Pregnancy and lactation eligibility Use is contraindicated during both pregnancy and the lactation period.
Condition-specific eligibility rules Use with caution is mandated for patients with low arterial blood pressure, kidney diseases, or liver disorders.

Connection to the overall eligibility profile

The regulatory instructions strictly define that use is contraindicated for specific high-risk groups (hypersensitive, pregnant, or lactating women). Furthermore, the medicine is not recommended for the pediatric population. The general adult population may use the drug, but specific conditions like low blood pressure and pre-existing liver or kidney diseases require the medicine to be used with caution.

Advertisements

What should I know about interactions with other medicines?

The official regulatory documents for Мебикар (Temgicoluril) define its interaction profile primarily through pharmacodynamic potentiation with other central nervous system (CNS) agents. No pharmacokinetic interactions, such as those involving cytochrome P450 enzymes or drug transporters, are formally documented in official prescribing information. Furthermore, there are no medicinal products or substances explicitly listed as contraindicated combinations due to interaction risk.

Interaction Class Description of Documented Outcome
Pharmacodynamic Interaction Co-administration with other CNS-active medicines may result in additive or potentiating effects on their therapeutic actions.
Interacting Categories This documented potentiation applies to medicine categories including Anxiolytics, Hypnotics, Neuroleptics (Antipsychotics), Antidepressants, Narcotic Analgesics, and Psychostimulants.

A specific substance interaction noted in regulatory labeling is with ethanol (alcohol). Official documentation specifies that Temgicoluril does not potentiate the effect of ethanol. No interactions are formally documented with food, supplements, or herbal products. The regulatory label does not specify mandatory dose separation requirements or any population-specific cautions regarding interaction severity in special groups. This interaction structure focuses solely on documented pharmacodynamic considerations.

Advertisements

Mechanism of Action

Мебикар is a bicyclic ureide, structurally distinct from benzodiazepine anxiolytics. Its mechanism involves engagement with the GABA-A receptor complex at a distinct allosteric site from the classical benzodiazepine binding location. This interaction alters the conformational state of the receptor, resulting in a pronounced, yet subtle, consequence on GABA-ergic transmission within the central nervous system. Further mechanistic investigations indicate that the compound interacts with central monoamine systems, influencing the dopamine and serotonin pathways. This influence modulates the steady-state concentrations of monoamines in the central nervous system. Additionally, the compound demonstrates an ability to lower circulating levels of adrenaline and noradrenaline, representing a systemic biochemical consequence of its action.

Advertisements

Dosage and Administration Information

Administration Guidelines for Мебикар

The administration of Temgicoluril (Mebicar) is primarily defined by the instructions provided for the compound, which standardize its procedural use.

Administration Scope Guideline Instruction
Route of Administration The routine method of administration is oral (by mouth).
Dosing Schedule Adults typically receive 300 mg to 500 mg per dose, taken 2 to 3 times per day. The highest single dose is not to exceed 3 grams (3,000 mg), and the maximum daily dose is 10 grams (10,000 mg). For supportive use during nicotine cessation, the daily dose generally ranges from 600 mg to 1000 mg.
Frequency and Timing The medicine may be taken independently of food intake (with or without meals).
Population-Specific Rules Dose adjustment is generally not required for older adults or patients with liver (hepatic) impairment. However, the medicine is not recommended for use in children and adolescents under 18 years of age. Caution is advised for patients with kidney (renal) impairment as dose adjustment data is limited.
Course Duration The general course of administration typically ranges from a few days up to 2 to 3 months. Use for nicotine cessation is usually prescribed for a fixed duration of 5 to 6 weeks.
Procedural Conditions If a dose is missed, the next scheduled dose is continued; a double dose should not be taken. If a tablet is scored, the line is intended for ease of swallowing and not for dividing the tablet into equal doses.

This protocol establishes a structured, multiple-times-daily oral regimen with defined limits, durations, and procedural guidance, thereby standardizing the use of the medication.

Advertisements

Recent Clinical Evidence

Мебикар: Recent Clinical Evidence

Research Evidence Overview

Research has explored the compound's role in modifying nerve signal transmission. Initial studies investigated the compound's interaction with specific signaling pathways. Studies also examined variables relevant to patient groups.

Phase-Specific Trial Design

Initial research on the compound examined changes in reported pain levels across multiple patient groups. Large-scale clinical trials have been instrumental in assessing the compound's profile. The primary trial objectives are summarized below:

Trial Phase Primary Research Focus Study Duration Examples
Phase 1 Pharmacokinetics and the limits of dose exploration Short-term (days to weeks)
Phase 2 Dose-ranging and preliminary investigation of measured variables Medium-term (weeks to months)
Phase 3 Investigation of changes in the clinical presentation in large patient groups Long-term (six months or more)

Safety Profile and Interactions

Research has focused on the safety profile by evaluating adverse events reported across all phases. Studies investigated variables potentially associated with severe adverse events when combining the compound with other substances. The outcomes from the compound groups were benchmarked against different treatment modalities in certain studies. Research is ongoing to identify specific patient populations that may experience varied outcomes.

Summary: Research continues to investigate the compound for various clinical indications.

Key Studies & References Clinical Efficacy and Safety of Mebicar in Patients with Neurotic Disorders: A Randomized Controlled Trial

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Мебикар (FAQ)

Q: Is Мебикар used for emotional distress, physical tension, or both?

The official documents describe the drug's purpose as psychological stabilization, mitigating emotional states such as tension, unrest, fear, and irritability. The medicine is primarily positioned for emotional regulation. Physical tension is generally not explicitly listed as a stand-alone, primary indication in the official product information.


Q: How long does it typically take for the effects of Мебикар to begin?

Studies based on the medicine's pharmacokinetic profile, which describes how it moves through the body, indicate the time to reach peak concentration is typically short. This maximum concentration in the bloodstream is generally achieved within 0.5 hours (30 minutes) after taking the medicine by mouth.


Q: Can Мебикар be taken safely with common vitamins, minerals, or dietary supplements?

Official documentation states that no interactions are formally documented with common food items, dietary supplements, or herbal products. The official prescribing information does not list mandatory restrictions regarding co-administration with these products.


Q: What is the official stance on the risk of tolerance or dependence with Мебикар?

Clinical literature focusing on the drug's safety profile indicates that Мебикар is not associated with developing tolerance. Furthermore, authoritative sources indicate the medicine is not associated with causing dependence.


Q: Can Мебикар cause withdrawal symptoms if stopped suddenly?

According to official clinical literature, the medicine is noted for its favorable profile regarding cessation. Clinical studies state that Мебикар is not reported to cause withdrawal symptoms upon cessation.


Q: Does the effectiveness of Мебикар decrease over time?

Official clinical studies state that the medicine is not associated with causing tolerance. This indication suggests that the issue of effectiveness diminishing over time due to tolerance is generally not associated with this medicine.


Q: Is Мебикар an addictive substance?

Concerns about addiction are addressed in official clinical literature. Official literature states that the medicine is not associated with causing dependence, which informs the risk profile regarding potentially addictive substances.


Q: Does Мебикар affect sleep patterns or cause insomnia?

The official profile indicates that the medicine has no direct effect on initiating sleep or causing insomnia. However, the medicine has been associated with improving existing sleep disturbances, which may contribute to more regulated sleep patterns.


Q: Is Мебикар ever prescribed for panic attacks?

The drug is officially indicated for reducing general states of fear and anxiety. However, the current official product information does not explicitly list 'panic attacks' as a specific indication.


Q: Can taking Мебикар cause headaches or dizziness?

Official safety information does not explicitly list headaches as a common or rare adverse event. However, the documentation notes that a transient decrease in blood pressure (hypotension) may occur. This documented effect may potentially be associated with feelings of dizziness.


Q: Is there a rebound effect or worsening of symptoms when stopping Мебикар?

Regulatory literature addresses the possibility of symptoms returning after stopping therapy. Clinical studies indicate that the medicine is not reported to cause withdrawal or dependence, which informs the profile regarding the potential for rebound effects upon cessation.

Advertisements

How should Мебикар be stored and disposed of?

How to Store and Dispose of Mebicar (Temgicoluril)

The official regulatory documentation strictly defines the conditions necessary to maintain the quality and stability of Mebicar tablets.

Storage Requirements

Requirement Type Official Condition
Temperature Store at a temperature not exceeding 25 C.
Protection Must be protected from moisture and light (direct sunlight).
Handling The product must not be refrigerated or frozen.
Container Must be stored in the original, tightly closed package.

Access and Disposal

The medicine must be kept out of the sight and reach of children.

Unused or expired Mebicar must be disposed of in accordance with local regulatory requirements for pharmaceutical waste and must not be discarded via wastewater or routine household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Мебикар found in:

A-Z Index: